Scientific Programme
Day 1 | Wednesday, 7 May 2025
| From 7:30 a.m. | Registration Counter open | |
| 09:00 - 09:15 a.m. | Opening remarks | Paul Hofman, France Klaus Pantel, Germany Catherine Alix-Panabières, France |
| 09:15 - 09:40 a.m. | Tracing tumor evolution by liquid biopsy | Klaus Pantel, Germany |
| Session 1 | Cancer Biology Moderated by: Janine Erler (Denmark) & Jean-Paul Thiery (France) | |
| 09:40 - 10:05 a.m. | Therapeutic strategies for advanced carcinoma Abstract | Jean-Paul Thiery, France |
| 10:05 - 10:30 a.m. | ECM regulation of metastasis Abstract | Janine Erler, Denmark |
| 10:30 - 11:10 a.m. | Coffee Break | |
| Session 2 | Cancer Immunology - Artificial Intelligence in Science & Medicine Moderated by: Núria Malats (Spain) & Paul Hofman (France) | |
| 11:10 a.m. - 11:35 p.m. | Liquid biopsy: pioneering the future of immuno-oncology with CTCs Abstract | Catherine Alix-Panabières, France |
| 11:35 a.m. - 12:00 p.m. | AI Horizons: from societal transformations to exploring new frontiers in AI for cancer research Abstract | Miguel Luengo Oroz, Spain |
| 12:00 p.m. - 12:15 p.m | Adherent-to-suspension transition, circulating tumor cells, and anti-metastatic therapy Abstract | Hyun Woo (Henry) Park, Republic of Korea |
| 12:15 p.m. - 12:30 p.m | Decoding the immune landscape of metastatic breast cancer via liquid biopsy Abstract | Keerthi Kurma, France |
| 12:30 - 02:00 p.m. | Lunch Break | |
| Session 3 | Minimal Residual Cancer Detection and Characterization Moderated by: Lilian S. Siu (Canada) & Klaus Pantel (Germany) | |
| 02:00 - 02:25 p.m. | Minimal residual disease in colon cancer: moving to the clinics | Clara Montagut, Spain |
| 02:25 - 02:50 p.m. | TRACERx insights into ultra-sensitive minimal residual disease detection Abstract | Charles Swanton, UK |
| 02:50 - 03:15 p.m. | Nation wide testing for ctDNA | Fabrice André, France |
| 03:15 - 03:30 p.m. | Circulating tumour cells and circulating tumour dna in patients with resectable colorectal liver metastases – a prospective cohort study (the miracle) Abstract | Lissa Wullaert, The Netherlands |
| 03:30 - 03:45 p.m. | Dynamic size and association profiles of tumour-derived dna during pancreatic cancer progression Abstract | Daniel Hagey, Sweden |
| 03:45 - 04:10 p.m. | MRD in head and neck cancer: circulating tumor and HPV DNA Abstract | Lilian L. Siu, Canada |
| 04:10 - 04:35 p.m. | ctDNA in context of clinical response | Luis Diaz, USA |
| 04:35 - 05:00 p.m. | Ultrasensitive ctdna analysis as a biomarker for immunotherapy response across multiple cancer types Abstract | Rodrigo Toledo, Spain |
| 05:15 - 06:45 p.m. | Poster Sessions with Coffee | |
Day 2 | Thursday, 8 May 2025
| Session 4 | Early Detection of Cancer Moderated by: Ellen Heitzer (Austria) & Nitzan Rosenfeld (UK) | |
| 09:00 - 09:25 a.m. | Sensitive detection of ctDNA | Nickolas Papadopoulos, USA |
| 09:25 - 09:50 a.m. | Epigenetic liquid biopsy Abstract | Yuval Dor, Israel |
| 09:50 - 10:15 a.m. | Smaller, cheaper, faster: where next for liquid biopsies Abstract | Nitzan Rosenfeld, UK |
| 10:15 - 10:30 a.m. | Prostate cancer PROLIPSY study - what we already know and what is yet to come Abstract | Joanna Budna-Tukan, Poland |
| 10:30 - 10:45 a.m. | Robust detection, classification, and monitoring of pediatric brain tumors from cell-free dna methylomes Abstract | Kendra Maaß, Germany |
| 10:45 - 11:15 a.m. | Coffee Break | |
| Session 5 | Liquid Biopsy and Immunotherapy Moderated by: Paola Gazzaniga (Italy) & Raphael López López (Spain) | |
| 11:15 - 11:40 a.m. | Liquid biopsy in cancer immunotherapy | Raphael López López, Spain |
| 11:40 a.m. - 12:05 p.m. | Monitoring immunotherapies with liquid biopsies: the experience of Sapienza University of Rome Abstract | Paola Gazzaniga, Italy |
| 12:05 - 12:30 p.m. | Ultra-sensitive ctDNA profiling in melanoma undergoing immune-checkpoint inhibition | Christoffer Gebhardt, Germany |
| 12:30 - 12:55 p.m. | Tumor fraction vs. other circulating predictive markers in NSCLC | Benjamin Besse, France |
| 12:55 - 01:10 p.m. | Predicting immunotherapy outcomes in endometrial cancer using multi-omic cell-free dna analysis Abstract | Julia Matas, Australia |
| 01:10 - 02:30 p.m. | Lunch Break | |
| Session 6 | Risk Assessment and Monitoring of Cancer Therapies Moderated by: Umberto Malapelle (Italy) & Sonja Loges (Germany) | |
| 02:30 - 02:55 p.m. | The role of liquid biopsy in immunotherapy response prediction and monitoring in NSCLC | Sonja Loges, Germany |
| 02:55 - 03:20 p.m. | Opportunities and challenges for clinical implementation of ctDNA testing | Nicola Normanno, Italy |
| 03:20- 03:45 p.m. | Real-world usefulness of CGP liquid biopsies on site in thoracic oncology Abstract | Paul Hofman, France |
| 03:45- 04:00 p.m. | Associations of circulating tumor cells with outcome in patients with her2-negative metastatic breast cancer treated with eribulin – results from the phase ii detect ivb trial Abstract | Wolfgang Janni, Germany |
| 04:00- 04:15 p.m. | The development and validation of the ultraseek gist panel on the massarray system for monitoring and detection of primary and secondary kit mutations in plasma-derived dna during targeted treatment of patients with gastrointestinal stromal tumors Abstract | Ed Schuuring, The Netherlands |
| 04:15 - 04:40 p.m. | Multidimensional evaluation of circulating tumor DNA Abstract | Umberto Malapelle, Italy |
| 04:40 - 05:05 p.m. | Clinical utility of liquid biopsy in breast cancer | Jean-Yves Pierga, France |
| 05:20 - 06:50 p.m. | Poster Sessions with Coffee | |
Day 3 | Friday, 9 May 2025
| Session 7 | Latest developments in Liquid Biopsy Moderated by: Rodrigo Toledo (Spain) | |
| 09:00 - 09:20 a.m. | EU diagnostics reimbursement challenges & solutions from the liquid biopsy point of view | Norbert Farkas, Switzerland |
| 09:20 - 09:40 a.m. | Use of ctDNA as a high risk biomarker in early-stage NSCLC | Chris Abbosh, UK |
| Session 8 | Perspectives of Liquid Biopsy - Part I Moderated by: Klaus Pantel (Germany) & Catherine Alix-Panabières (France) | |
| 09:40 - 10:05 a.m. | Inferring complex tumor states in lung cancer using cfDNA methylation from liquid biopsies | Simon Heeke, USA |
| 10:05 - 10:30 a.m. | Transforming cancer patient management: the intersection of AI and liquid biopsy | Nuria Malats, Spain |
| 10:30 - 10:55 a.m. | Extracellular vesicles | An Hendrix, Belgium |
| 10:55 a.m. - 11:25 a.m. | Coffee Break | |
| Perspectives of Liquid Biopsy - Part II Moderated by: Klaus Pantel (Germany) & Catherine Alix-Panabières (France) | ||
| 11:25 - 11:50 a.m. | Establishing a recurrence prevention measure for colorectal cancer after radical surgery by targeting the tumor microenvironment Abstract | Koshi Mimori, Japan |
| 11:50 a.m. - 12:15 p.m. | Credentialing liquid biopsies to accelerate drug development and inform medical decisions Abstract | Howard Scher, USA |
| 12:15 - 12:40 p.m. | Multimodal liquid biopsy analysis in children with cancer using long-read sequencing on a national scale Abstract | Carolin Sauer, UK |
| 12:40 - 01:05 p.m. | Scientific and clinical aspects of using ctDNA MRD in oncology Abstract | Karen-Lise Garm-Spindler, Denmark |
| 01:05 - 01:30 p.m. | Advancements in Liquid Biopsy: latest capabilities and clinical applications | Arndt Vogel, Germany |
| 01:30 - 01:40 p.m. | Young Investigator Awards | |
| 01:40 - 01:50 p.m. | Concluding Remarks | Paul Hofman, France Klaus Pantel, Germany Catherine Alix-Panabières, France |